Gender differences in the health related quality of life of older adults with heart failure

OBJECTIVE: The objective of this study was to explore whether gender differences exist in health-related quality of life for older adult men and women with heart failure. DESIGN: A secondary data analysis was conducted on an existing dataset of heart failure patients. The original study used an exploratory, correlational longitudinal design. SUBJECTS: 138 subjects (69 men and 69 women) with heart failure completed both data points of the study. RESULTS: Men and women were similar on the number and types of heart failure-related symptoms they experienced. Twenty-seven percent of the subjects could be classified as depressed. The men had better physical functioning than the women did with gender making a greater contribution to physical functioning than age or marital status. Twenty-three percent of the subjects were rehospitalized 4 to 6 weeks after the initial hospital discharge. CONCLUSIONS: This study showed that the health related quality of life for older men and women with heart failure is significantly impacted by heart failure. Older men and women have similar heart failure symptoms, depression, and rehospitalization following a hospital admission for heart failure. Both older men and older women with heart failure have impairments in their physical functioning with older women more physically impaired than older men.     

Quality of life in patients with heart failure: do gender differences exist?

OBJECTIVE: The purpose of this study was to evaluate gender differences in quality of life (QOL) in a large sample of age-matched and ejection fraction (EF)-matched patients with heart failure. DESIGN: Matched comparisons of secondary data were used. SETTING: The setting consisted of multicenter Studies of Left Ventricular Dysfunction trials. SAMPLE: The sample included 1382 patients (691 men and 691 women) who were age-matched and EF-matched.Outcome Measures: Global QOL and the QOL dimensions of physical function, emotional distress, social health, and general health were measured using the Ladder of Life, items from the Profile of Mood States Inventory, the Functional Status Questionnaire, the beta-Blocker Heart Attack Trial instrument, and an item from the RAND Medical Outcomes Study instrument. RESULTS: Women had significantly worse general life satisfaction, physical function, and social and general health scores than men. There were no significant differences found between gender groups for current life situation or emotional distress. After controlling for New York Heart Association classification, women still had significantly worse ratings for intermediate activities of daily living (a sub-dimension of physical functioning) and social activity. CONCLUSIONS: Despite controlling for age, EF, and New York Heart Association classification, women had worse QOL ratings than did men for intermediate activities of daily living and social activity. Research should focus on identifying why differences exist and developing measures to improve QOL, particularly physical functioning, in women with heart failure.     

Use of bisoprolol in heart failure. The BISOCOR observational study

INTRODUCTION AND OBJECTIVES: The benefits of beta blockers in heart failure are highly dependent on dosage. This study aimed to analyze the degree of concordance between targeted (CIBIS II) and achieved doses of bisoprolol in a group of patients with stable heart failure on conventional treatment. We also evaluated functional parameters, adverse effects and the reasons for withdrawal or drop-out. PATIENTS AND METHOD: The study group consisted of 334 patients with stable systolic heart failure who were receiving conventional treatment. Treatment with bisoprolol was initiated according to current guidelines (starting dose 1.25 mg/day, with weekly increments to 5 mg/day, and then increments every four weeks to a targeted dosis of 10 mg/day). The main endpoint was the comparison between targeted dose and dose reached at each follow-up. Secondary endpoints were quality of life assessment (Minnesota Living with Heart Failure Questionnaire), functional status (New York Heart Association), ejection fraction change, and side effects during the 9-month follow-up period. RESULTS: Thirty-four (10%) patients did not finish the study: 1 because of sudden death, 2 because of surgery, and 31 because of side effects. 63% of the patients attained the maximum targeted dose; the mean dose at the end of follow-up was 8.5 mg. Functional status, quality of life and ejection fraction improved significantly between the beginning and the end of the study. Only 4 patients had severe adverse effects. CONCLUSIONS: This is the first study in Spain to show that bisoprolol can be used effectively at the maximum recommended doses, for the outpatient treatment of heart failure.     

Biventricular pacing improves quality of life and exercise tolerance in patients with heart failure and intraventricular conduction delay

Background: Biventricular pacing improves left ventricular dysynchrony, leading to improvement in congestive heart failure symptoms. The extent of placebo effect, the predictors of response and the long term benefits are unknown. Patients and Methods: Forty-five patients with symptomatic congestive heart failure underwent implantation of a biventricular pacing system over a 30-month period (age 65 10 years, 37 men). Patients underwent implantation of a biventricular pacemaker or implantable defibrillator one month or longer after stabilization of congestive heart failure on maximal medical therapy, including angiotensin-converting enzyme inhibitors in 84% of patients and beta-blockers in 56% of patients. Three patients had New York Heart Association (NYHA) class II heart failure, 34 had NYHA class III and eight had NYHA class IV. Cardiomyopathy was ischemic in 31 patients, dilated in 12 and the result of other causes in two. The left ventricular ejection fraction was 19 5%. Results: Implantation of the biventricular pacing system was successful in 38 of 45 patients (84%). Two patients had successful implantation with a second attempt, and one patient had an epicardial lead implant. Lead dislodgement occurred in four patients, with successful repositioning in all. During a mean follow-up of 10 7 months, the Minnesota Living with Heart Failure Questionnaire quality of life index score improved from 62 16 to 42 22 at one month (P<0.001), but subsequently returned to intermediate levels (55 26 at three months, 48 26 at six months and 56 34 at one year, P=0.50). In seven patients with deferred device activation, quality of life scores also improved by 10 15 points from baseline to one month with VDI 35 pacing, and improved a further 15 20 points with left ventricular lead activation. The mean NYHA class fell from 3.1 0.5 at baseline to 2.7 0.7 at one month (P=0.006) and remained stable thereafter (2.8 0.9 at three months, 2.8 0.9 at six months). Six patients died during follow-up, one patient had a cardiac transplantation and subsequently died, one patient had a successful cardiac transplantation and one patient underwent insertion of a left ventricular assist device. Death occurred due to progressive heart failure in five patients, sudden death occurred in one patient and a noncardiovascular cause resulted in the death of one patient. An analysis of NYHA responders (NYHA class improvement of 1 or more at last follow-up, 44% of patients) and quality of life responders (score improvement of 10 or more at last follow-up, 57% patients) did not show any difference in age, sex, heart failure etiology, QRS width, ejection fraction or baseline NYHA class. Conclusions: Biventricular pacing improves quality of life and NYHA class in patients with advanced heart failure and intraventricular conduction delay. The attenuated benefit seen over time may be related to initial placebo effect or simple dual- chamber pacing, or the natural history of the underlying disease. Identification of patients most likely to respond to biventricular pacing was not possible.     

Systolic function as a predictor of mortality and quality of life in long-term survivors with heart failure

BACKGROUND: Patients with heart failure (HF) and preserved ejection fraction (EF) have been shown to have high mortality rates, comparable to those with reduced EF. Thus, long-term survivors of HF, regardless of ejection fraction, are a select group. Little is known about disease-related quality of life (QOL) and health status in these patients. HYPOTHESIS: Preserved EF in patients with heart failure independently predicts long-term survival, health related quality of life (QOL), or functional status. METHODS: The study followed a cohort of 413 patients consecutively hospitalized for HF between March 1996 and September 1998. In July 2005, information was collected about their mortality, health related QOL as defined by disease-specific Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, and functional decline as defined by limitations in Activities of Daily Living (ADL) scores. RESULTS: The primary outcomes were mortality, QOL, and functional decline. At follow-up, 8.1 years after enrollment, overall mortality was 76% (314/413). Adjusted for age, gender, renal insufficiency, diabetes mellitus, hypertension, HF, and respiratory disease, those with decreased ejection fraction (EF < 40%) had higher mortality compared with those with preserved ejection fraction (hazard ratio [HR] 1.42; confidence interval [CI] = 1.13, 1.80, p = 0.003). The KCCQ scores, including Clinical Summary Scores and Symptom Limitation Scores, as well as ADL limitations, were not significantly different in the survivors with preserved or decreased EF. CONCLUSIONS: Heart failure patients with preserved EF have a modest survival advantage compared with those with decreased EF, but health related QOL scores and functional decline in survivors are similar regardless of systolic function.     

Long-term follow-up of very old heart failure patients enrolled in a trial of exercise training

Little is known about how physical and psychological status changes with time in older heart failure patients. The authors followed up a cohort of 82 patients (mean age, 80.5 years) enrolled in a randomized controlled trial of exercise training in heart failure. Six-minute walk test, accelerometry, functional status, quality of life, anxiety, and depression were measured at baseline, 3 months, 6 months, and a mean of 19 months post-enrollment. There were no significant differences between the exercise and control groups at long-term follow-up. Six-minute walk distance declined by only 0.2 m/month in those attending final follow-up (vs 4.6 m/month in nonattenders; P=.03). Similar results were seen for other outcomes. Only a small proportion of the variance in change of any of the outcomes was explained by differences in baseline variables.     

Effects of tai chi mind-body movement therapy on functional status and exercise capacity in patients with chronic heart failure: a randomized controlled trial

PURPOSE: To examine the effects of a 12-week tai chi program on quality of life and exercise capacity in patients with heart failure. METHODS: Thirty patients with chronic stable heart failure and left ventricular ejection fraction < or =40% (mean [+/- SD] age, 64 +/- 13 years; mean baseline ejection fraction, 23% +/- 7%; median New York Heart Association class, 2 [range, 1 to 4]) were randomly assigned to receive usual care (n = 15), which included pharmacologic therapy and dietary and exercise counseling, or 12 weeks of tai chi training (n = 15) in addition to usual care. Tai chi training consisted of a 1-hour class held twice weekly. Primary outcomes included quality of life and exercise capacity. Secondary outcomes included serum B-type natriuretic peptide and plasma catecholamine levels. For 3 control patients with missing data items at 12 weeks, previous values were carried forward. RESULTS: At 12 weeks, patients in the tai chi group showed improved quality-of-life scores (mean between-group difference in change, -25 points, P = 0.001), increased distance walked in 6 minutes (135 meters, P = 0.001), and decreased serum B-type natriuretic peptide levels (-138 pg/mL, P = 0.03) compared with patients in the control group. A trend towards improvement was seen in peak oxygen uptake. No differences were detected in catecholamine levels. CONCLUSION: Tai chi may be a beneficial adjunctive treatment that enhances quality of life and functional capacity in patients with chronic heart failure who are already receiving standard medical therapy.     

双心室再同步起搏治疗宽QRS慢性心力衰竭患者的长期疗效及病死率分析

目的观察双心室同步起搏治疗慢性心力衰竭(心衰)患者的长期疗效及死亡率.方法 2001年3月至2005年2月住院患者25例,男18例,女7例,年龄34～75(61.42±10.36)岁;其中扩张性心肌病16例,高血压性心脏病3例,缺血性心肌病6例,心功能NYHA分级Ⅲ级10例、Ⅳ级15例.所有患者左室舒张末期内径(LVEDD)>60 mm,左室射血分数(LVEF)<0.40,QRS>130 ms.观察术前及术后3个月、6个月、1年、2年、3年的心功能各项参数及死亡率,平均随访时间为(20.88±11.51)个月.结果 (1)死亡率死亡5例,非心原性死亡3例,心原性猝死1例,急性心肌梗死1例.(2)术后3个月至3年,平均6 min步行距离明显增加(P<0.01).(3)NYHA心功能分级,术后3个月至3年,心功能明显改善(P<0.01),平均心功能降低1级以上.(4)LVEDD术后3个月至3年,LVEDD明显减小(P<0.05～P<0.01).(5)LVEF术后3个月至2年,LVEF明显增加(P<0.05～P<0.01);术后第3年 ,LVEF也改善,但差异无统计学意义.结论双心室同步起搏治疗宽QRS慢性心衰能明显改善患者的生活质量及心功能,减少LVEDD,逆转左室重构,长期治疗疗效巩固,并能降低心衰导致的病死率.     

Use of the Minnesota Living With Heart Failure Quality of Life Questionnaire in Spain

INTRODUCTION AND OBJECTIVES: Quality of life is an important end-point in heart failure studies, as well as mortality and hospitalization rates. The Minnesota Living With Heart Failure Questionnaire is the instrument used most widely to evaluate quality of life in research studies. We used this questionnaire to evaluate quality of life in a general population attended by a heart failure unit in Spain. PATIENTS AND METHOD: 326 patients seen for the first time at the unit were evaluated. We analyzed the relationship between the questionnaire score and different clinical and demographic factors. RESULTS: The median global score on the Minnesota Living With Heart Failure Questionnaire was relatively low (28). We found a strong correlation (P<.001) between the score and functional class, sex (women had higher scores), and diabetes. We also found a correlation between the score and number of hospital admissions in the previous year (P<.001), anemia (P<.001) and etiology (P=.01), and a weak trend toward higher scores with increasing age (P=.04). The highest scores were observed in patients with valve disease disorders (43), and the lowest were seen in patients with alcoholic cardiomyopathy (20) and ischemic heart disease (24). We found no correlation with time of evolution of heart failure or with left ventricular ejection fraction. CONCLUSIONS: The scores on the Minnesota Living With Heart Failure Questionnaire in a general population attended by a heart failure unit in Spain were relatively low. However, we found a strong correlation between this score and functional class, and also between this score and number of admissions in the previous year. These results suggest that the questionnaire adequately reflects the severity of the disease.     

Sex Differences in Exercise Capacity and Quality of Life in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of the RELAX and NEAT-HFpEF Trials

BackgroundFew studies have compared clinical characteristics, echocardiographic parameters, exercise capacity, and quality of life between women and men with heart failure with preserved ejection fraction (HFpEF).Methods and ResultsSubjects in the NIH-sponsored RELAX (N = 216) and NEAT (N = 107) trials completed baseline echocardiography, the Minnesota Living with Heart Failure Questionnaire (MLHFQ), and 6-minute walk test (6MWT). In an exploratory analysis, multivariable linear regression models were used to associate clinical and imaging characteristics with baseline 6MWT distance and MLHFQ score in women and men. Our cohort included 158 (49%) men and 165 (51%) women. Men had higher prevalence of atrial arrhythmias, ischemic heart disease, diabetes, anemia, and left ventricular (LV) hypertrophy. 6MWT and MLHFQ score did not differ between sexes. In multivariable analysis, ischemic heart disease, diastolic dysfunction, and exercise capacity predicted MLHFQ score for men, whereas only age and body mass index predicted MLHFQ score for women.ConclusionsMen with HFpEF had more comorbidities and LV hypertrophy than women with HFpEF. In men, quality of life was associated with diastolic dysfunction, ischemic heart disease, and exercise capacity. Further research is needed to identify determinants of quality of life in women with HFpEF.     

Effect of physical training on exercise capacity, gas exchange and N-terminal pro-brain natriuretic peptide levels in patients with chronic heart failure.

BACKGROUND: Decreased exercise capacity is the main factor restricting the daily life of patients with chronic heart failure. N-terminal pro-brain natriuretic peptide (NT pro-BNP) is strongly related to the severity of and is an independent predictor of outcome in chronic heart failure. DESIGN: The study aimed to evaluate the effect of exercise training on functional capacity and on changes in NT pro-BNP levels and to assess the effect of exercise training on quality of life. MATERIALS AND METHODS: Sixty patients (45 men/15 women, mean age 52.7 years; +/-5.3 SD), with stable heart failure (45 ischaemic/hypertensive and 15 idiopathic patients), in New York Heart Association (NYHA) functional class II (n=35) to III (n=25), with an ejection fraction less than 40%, were randomly assigned to a training (n=30) and a control group (n=30). The training group (30 patients) performed 3 months of supervised physical training programme using a bicycle ergometer for 30 min three times a week at a load corresponding to 60-70% of their oxygen consumption (VO2) peak. The control group did not change their previous physical activity. A graded maximal exercise test with respiratory gas analysis and an endurance test with constant workload corresponding to 85% of the peak oxygen load at the baseline and after 3 months were performed, and at the same times NT pro-BNP levels were measured. RESULTS: The exercise capacity increased from 15.8 (+/-2.3 SD) to 29.9 (+/-2.1 SD) min (P<0.0001) and the peak VO2 tended to improve from 14.5 (+/-1.4 SD) to 17.7 (+/-2.6 SD) ml/kg per min (P<0.0001) during the supervised training period. VO2 at the anaerobic threshold increased from 12.9 (+/-1.0 SD) to 15.5 (+/-1.7 SD) ml/kg per min (P<0.0001). NT pro-BNP levels decreased from 3376 (+/-3133 SD) to 1434 (+/-1673 SD) pg/ml (P=0.043). The positive training effects were associated with an improvement in the NYHA functional class. CONCLUSION: Physical training of moderate intensity significantly improves the exercise capacity and neurohormonal modulation in patients with chronic heart failure. This is associated with an alleviation of symptoms and improvement in quality of life.     

Effect of mibefradil on heart rate variability in patients with chronic heart failure

BACKGROUND: Mibefradil was recently withdrawn from the market because of an unfavorable clinical profile in patients with chronic heart failure. Although drug interactions appear to play a role, other mechanisms such as proarrhythmia and autonomic deterioration could also be relevant. Chronic heart failure is accompanied by autonomic impairment and analysis of heart rate variability can be used to examine autonomic modulation of heart rate. METHODS: We studied 18 heart failure patients (age 63.2+/-10.1 years (mean+/-S.D. ), ejection fraction 0.21+/-0.07) treated with mibefradil or placebo, who participated in the MACH-I (Mortality Assessment in Chronic Heart failure) trial in our center, and compared them with 18 healthy matched controls. Heart rate variability analysis was performed at baseline and after 7 months of treatment. RESULTS: At baseline, heart rate variability parameters were impaired in patients with heart failure compared to healthy controls (P<0.05). After 7 months of treatment a reduction in (24-h) heart rate was observed (P=0.02, versus placebo). Apart from the effect on mean NN, no significant differences were observed for the remaining heart rate variability parameters. CONCLUSIONS: Mibefradil does not impair autonomic balance and in fact reduces heart rate in patients with heart failure. These findings suggest that autonomic activation did not contribute to the adverse effects of mibefradil.     

Self-care and quality of life in patients with advanced heart failure: the effect of a supportive educational intervention

OBJECTIVE: The goal of this study was to determine the effects of a supportive educational nursing intervention on self-care abilities, self-care behavior, and quality of life of patients with advanced heart failure. DESIGN: The study design was an experimental, random assignment. SETTING: The study was located at the University Hospital in Maastricht, The Netherlands. PATIENTS: The study included 179 patients (mean age 73 years, 58% men, New York Heart Association classification III and IV) admitted to a university hospital with symptoms of heart failure. OUTCOME MEASURES: Outcome measures included self-care abilities (Appraisal of Self-care Agency Scale), self-care behavior (Heart Failure Self-care Behavior Scale), 3 dimensions of quality of life (functional capabilities, symptoms, and psychosocial adjustment to illness), and overall well-being (Cantril's ladder of life). INTERVENTION: The intervention patients received systematic education and support by a nurse in the hospital and at home. Control patients received routine care. RESULTS: Self-care abilities did not change as a result of the intervention, but the self-care behavior in the intervention group was higher than the self-care behavior in the control group during follow-up. The effect of the supportive educational intervention on quality of life was limited. The 3 dimensions of quality of life improved after hospitalization in both groups, with no differences between intervention and control group as measured at each follow-up measurement. However, there was a trend indicating differences between the 2 groups in decrease in symptom frequency and symptom distress during the 9 months of follow-up. CONCLUSION: A supportive educational nursing intervention is effective in improving self-care behavior in patients with advanced (New York Heart Association class III-IV) heart failure; however, a more intensive intervention is needed to show effectiveness in improving quality of life.     

Five-year follow-up findings from a randomized controlled trial of cardiac rehabilitation for heart failure.

BACKGROUND: A follow-up study was carried out on the 5-year status of the surviving patients (n=179 at 6 months) of a 24-week randomized controlled trial comparing cardiac rehabilitation (CR) with heart failure outpatient clinic care (standard care). METHODS: In the original randomized controlled trial, 200 patients (60-89 years, 132 men) with New York Heart Association II/III heart failure confirmed by echocardiography had been randomized (2000-2001). At the 5-year follow-up, the initial trial measures (6-min walk test, Minnesota living with heart failure, EuroQol health-related quality of life, and routine biochemistry) were repeated if the patient was in a satisfactory condition. Data on deaths and admissions were obtained from the medical records department. RESULTS: Over half of the original participants (n=119, 59.5%) were alive at 5 years (mean age 75.2 years), and most (94%) attended the clinic for assessment. A sustained improvement from baseline for both groups in Minnesota living with heart failure, but not in EuroQol was observed, and the majority of the other measures had deteriorated. In contrast to the CR group, the standard care group showed a significant deterioration in walking distance (5 versus 11%; P<0.05). More patients in the CR group were taking regular exercise (71 versus 51%; P<0.05). No significant differences between the groups in health care utilization or survival were observed. CONCLUSION: A 24-week CR programme for patients with stable heart failure showed some long-term benefit at 5 years. Differences in the mean values of most of the functional and quality of life measures were evidently to the advantage of the CR group, which also showed a better exercise profile.     

The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design

BACKGROUND: Although 40% to 50% of patients with chronic heart failure (HF) have relatively preserved systolic function (PSF), few trials have been conducted in this population and treatment guidelines do not include evidence-based recommendations. METHODS AND RESULTS: The Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) is enrolling 4100 subjects with HF-PSF to evaluate whether 300 mg irbesartan is superior to placebo in reducing mortality and prespecified categories of cardiovascular hospitalizations. The principal inclusion criteria are age > or =60 years, heart failure symptoms, an ejection fraction > or =45%, and either hospitalization for heart failure within 6 months or corroborative evidence of heart failure or the substrate for diastolic heart failure. Additional secondary end points include cardiovascular mortality, cause-specific mortality and morbidity, change in New York Heart Association functional class, quality of life, and N-terminal pro-BNP measurements. Follow-up will continue until 1440 patients experience a primary end point. Substudies will evaluate changes in echocardiographic measurements and serum collagen markers. CONCLUSION: I-PRESERVE is the largest trial in this understudied area and will provide crucial information on the characteristics and course of the syndrome, as well as the efficacy of the angiotensin receptor blocker irbesartan.     

双室起搏治疗充血性心力衰竭近期疗效研究

为进一步观察双室起搏对充血性心力衰竭 (简称心衰 )治疗的效果 ,对 10例充血性心衰病人置入InSync(三腔 )起搏器 ,并观察术前及术后 3个月临床症状及心功能指标的情况。结果 :置入起搏器术后 3个月 ,心功能明显改善 ,从 3.4 4± 0 .5 2级降至 1.5 0± 0 .72级 (P <0 .0 1) ,心衰症状评分从 8.1± 3.2 9分降至 1.4± 1.74分 (P <0 .0 1) ,左室舒张末期内径从 6 7± 6 .6 8mm减至 6 2 .75± 5 .92mm(P <0 .0 5 ) ,射血分数从 0 .35± 0 .0 7增至 0 .4 3± 0 .10 (P <0 .0 5 )。结论 :双室起搏治疗可明显改善心功能 ,提高病人生活质量 ,逆转左室重塑。     

Effects of the HEART Camp Trial on Adherence to Exercise in Patients With Heart Failure

Background

Few exercise training studies in patients with heart failure (HF) report adherence to guideline-recommended 150 minutes of moderate-intensity exercise per week, and no studies have focused on a primary outcome of adherence.

Quality of life and cardiorespiratory function in chronic heart failure: effects of 12 months' aerobic training.

OBJECTIVE: To examine the long-term benefits and safety of aerobic training in patients with chronic heart failure. DESIGN: Non-randomised control trial with 52 weeks follow up. SETTING: Outpatient cardiac rehabilitation referral centre. PATIENTS: Patients with compensated chronic heart failure (mean (SD) age 62 (6) years, New York Heart Association stage III, initial resting ejection fraction 22 (7)%). Experimental group of 17 men, 4 women; control group 8 men, 1 woman. INTERVENTIONS: Experimental group: progressive, supervised aerobic walking programme for 52 weeks. Control group: standard medical treatment. MAIN OUTCOME MEASURES: Six-minute walk distance, progressive cycle ergometer test to subjective exhaustion, disease-specific quality of life questionnaire, and standard gamble test, all measured at entry, 4, 8, 12, 16, 26, and 52 weeks. RESULTS: Control data showed no changes except a small trend to improved emotional function (P = 0.02 at 12 weeks only). Fifteen of the 21 patients completed all 52 weeks of aerobic training; two withdrew for non-cardiac reasons (16, 52 weeks). Three were withdrawn because of worsening cardiac failure unrelated to their exercise participation (4, 4, 8 weeks), and one had a non-fatal cardiac arrest while shopping (16 weeks). Gains of cardiorespiratory function plateaued at 16-26 weeks, with 10-15% improvement in six-minute walk, peak power output, and peak oxygen intake linked to gains in oxygen pulse and ventilatory threshold and reductions in resting heart rate. Marked improvements in quality of life followed a parallel course. CONCLUSIONS: Aerobic training is safe and beneficial in compensated chronic heart failure. Gains in aerobic function and quality of life persisted over a programme lasting 52 weeks.